Biotechnology
Medical
Biopharmaceutical

GTx

$1.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-4.17%) Today
+$0.01 (0.87%) After Hours

Why Robinhood?

You can buy or sell GTx and other stocks, options, ETFs, and crypto commission-free!

About

GTx, Inc. Common Stock, also called GTx, is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. Read More It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

Employees
21
Headquarters
Memphis, Tennessee
Founded
1997
Market Cap
28.86M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
908.33K
High Today
$1.19
Low Today
$1.11
Open Price
$1.19
Volume
232.97K
52 Week High
$25.60
52 Week Low
$0.74

Collections

Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
Cancer Prevention

News

Markets InsiderMar 11

GTX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of GTx, Inc. - GTXI

NEW ORLEANS, March 11, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of GTx, Inc. (NasdaqCM: GTXI) with Oncternal Therapeutics, Inc. in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction undervalues the Company and/or if you wo...

3,286
BusinessWireMar 7

GTX, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

WILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A.: Do you own shares of GTx, Inc. (NASDAQ CM: GTXI )? Did you purchase any of your shares prior to March 7, 2019? Do you think the proposed merger is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of GTx, Inc. (“GTx” or the “Company”) (NASDAQ CM: GTXI) regarding possible breaches of fiduciary duties and other violations of law related to the ...

248
Yahoo FinanceMar 7

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of GTx, Inc. to Oncternal Therapeutics, Inc. is Fair to Shareholders

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased GTx, Inc. (“GTx” or the “Company”) (GTXI) stock prior to March 6, 2019 . You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of GTx to Oncternal Therapeutics, Inc. (“Oncternal”). Under the terms of the transaction, GTx shareholders will receive shares in Oncternal equal to 25% of the outstandin...

2,607

Earnings

-$0.62
-$0.41
-$0.21
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.22 per share
Actual
Expected Mar 27, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.